Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kagoshima University manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio is currently navigating 4 pending office actions, indicating a level of ongoing interaction with the patent office. These 4 actions are distributed across 4 distinct examiners and 4 distinct art units. This ratio between actions, examiners, and art units suggests a diversified portfolio where every pending matter is being evaluated independently by a different specialist in a different administrative group.
The busiest examiner for the university is MELENDEZ, ARMAND, who is currently handling 1 busiest examiner pending action. In the context of 4 total pending office actions, the workload is balanced, with no single examiner or art unit holding a majority of the cases. This level of dispersion across 4 distinct art units is notable, as it suggests the university's research spans a variety of pharmaceutical or biotechnological disciplines. For a practitioner, this diversity means that the prosecution strategy must be tailored to four different sets of examiner preferences and art unit norms. Each of the distinct examiners manages a single action within the 4 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MELENDEZ, ARMAND | 1 | 46.2% | +43.1% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770978 | METHOD FOR PRODUCING MONOVALENT CCAP PRODUCT | REDDIG, PETER J | 7d |
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | HAVLIN, ROBERT H | 26d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17770978 | METHOD FOR PRODUCING MONOVALENT CCAP PRODUCT | REDDIG, PETER J | 7d |
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | HAVLIN, ROBERT H | 26d |
| 18569175 | CAPSULE PRODUCTION METHOD AND CAPSULE PRODUCTION DEVICE | MELENDEZ, ARMAND | — |
| 18548807 | HB-EGF GENE THERAPY FOR DIABETES | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1759 | 1 |
| 1638 | 1 |
| 1646 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569175 | CAPSULE PRODUCTION METHOD AND CAPSULE PRODUCTION DEVICE | MELENDEZ, ARMAND | 1759 | §103 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18548807 | HB-EGF GENE THERAPY FOR DIABETES | MCCORMICK, CATHERINE LYNN | 1638 | §103 | Final Rejection | — | Pending | Sep 01, 2023 |
| 17770978 | METHOD FOR PRODUCING MONOVALENT CCAP PRODUCT | REDDIG, PETER J | 1646 | §102§103 | Final Rejection | 7d | Pending | Apr 21, 2022 |
| 17430557 | ANTIPRURITIC AGENT USING PAC1 RECEPTOR ANTAGONIST | HAVLIN, ROBERT H | 1626 | §103§112 | Non-Final OA | 26d | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial